1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Ruxolitinib
Trade Name:
Jakavi
Manufacturer/Distributor:
Novartis
www.novartis.ca
Classification:
Antineoplastic agent
JAK 1, 2 inhibitor; protein kinase inhibitor
ATC Class:
L01XE18 - ruxolitinib
Status:
active
Notice of Compliance (yyyy/mm/dd):
2012/06/19
Date Marketed in Canada (yyyy/mm/dd):
2012/07/18
Presentation:
Tablet: 5 mg. DIN: 02388006
Tablet: 15 mg. DIN: 02388014
Tablet: 20 mg. DIN: 02388022
Comments:
Ruxolitinib is indicated for the treatment of splenomegaly in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Back to:
Drug Product Listings 
